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Abstract
Cancer associated fibroblasts (CAFs) play a critical role for growth, invasion, and metastasis of cancer. Therefore, 
targeting CAFs with small molecule inhibitors may be an attractive anti-tumor strategy. The current study aims to 
identify small molecule kinase inhibitors affecting CAF's growth and to characterize the biological effects of active 
compounds on primary CAFs from lung cancer. We screened two individual CAF strains for their sensitivity to a panel of 
160 kinase inhibitors. Five kinase inhibitors were identified inhibiting more than 50% of the growth of both cell lines. 
Three of them were inhibitors of PDGFR at nanomolar concentrations. Therefore, we further tested the FDA approved 
PDGFR inhibitors Dasatinib, Nilotinib, Sorafenib, and Imatinib. All 37 CAF strains investigated were highly sensitive to 
Dasatinib at clinically relevant concentrations. Imatinib was slightly less effective, whereas the inhibitory effects of 
Nilotinib and Sorafenib were significantly less pronounced.
We investigated the effect of Dasatinib on the CAF transcriptome by microarray analysis of 9 individual CAF strains. 492 
genes were identified whose expression was changed at least twofold. 104 of these encoded cell cycle related proteins 
with 97 of them being downregulated by Dasatinib. The majority of regulated genes, however, were of diverse 
biological functions not directly related to proliferation. We compared this Dasatinib expression signature to previously 
described differential signatures of normal tissue associated fibroblasts (NAFs) and CAFs and to a signature of fibroblast 
serum response. There was a significant overlap between genes regulated by Dasatinib and serum repression genes. 
More importantly, of the 313 genes downregulated by Dasatinib 64 were also reduced in NAFs compared to CAFs. 
Furthermore, 26 of 179 genes identified as upregulated by Dasatinib were also found to be elevated in NAFs compared 
to CAFs. These data demonstrate that Dasatinib partially reverses the phenotype of CAFs to a normal fibroblast like 
phenotype. This is further supported by the finding that incubation of tumor cells with conditioned medium from 
CAFs pre-incubated with Dasatinib significantly reduced tumor cell proliferation, suggesting that Dasatinib partially 
reverses the CAF mediated tumor promoting effect. Therefore, targeting CAFs with Dasatinib represents a promising 
therapeutic principle.
Findings
The tumor microenvironment or "stroma" actively partic-
ipates in tumorigenesis, tumor progression, and metasta-
sis. Within the tumor stroma, CAFs are of outstanding
importance. CAFs are the primary cell type that produces
ECM and thereby determines dynamics of the tumor [1].
CAFs show a molecular and functional phenotype that
is different from NAFs. It has been early recognized by
pathologists that in many tumors stroma is characterized
by an increased fibroblast proliferation [2]. CAFs also
secrete a variety of growth factors and proteinases facili-
tating tumor growth and invasion [3-5]. The protective
and supportive effects of CAFs on tumor cells strongly
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support the concept that CAFs represent an attractive
target for anticancer therapy. The activity of a plethora of
kinases is involved in signalling pathways important for
the tumor promoting activities of CAFs including recep-
tors for PDGF and TGFβ and corresponding downstream
signal transducers [1]. Therefore, we investigated the
potency of kinase inhibitors to block CAF activities.
We screened a library of 160 kinase inhibitors at low
concentration (Additional file 1, Material and Methods)
for their effect on proliferation and viability of CAFs iso-
lated from 2 primary lung cancer specimens (Figure 1A).
The most potent compounds with a growth inhibition of
more than 50% in both tested CAF strains turned out to
be Staurosporine (broad spectrum inhibitor also inhibit-
ing PDGFR), one PDK1/Akt/Flt inhibitor, K-252a (inhib-
iting CaM kinase, PKC/PKA, and PDGFR at 100 nM), PI-
103 (PI3K/mTOR inhibitor), and one specific PDGFR
inhibitor (Additional file 2, Table S1). Thus, 3 of these 5
active inhibitors antagonize PDGFR activity at nanomo-
lar concentrations. These data show that, even under
conditions of high serum concentrations, PDGFR signal-
ing is a critical pro-proliferative stimulus for CAFs in
vitro. This finding is in accordance with earlier studies
demonstrating that PDGF plays a central role in desmo-
plasmic reaction in a breast cancer xenograft model [6].
While most epithelial tumor cells lack the PDGFR but
secrete PDGF, PDGFR is frequently found on CAFs and
expression of activated PDGFR is associated with meta-
static potential in colon carcinomas [7]. Targeting
PDGFR may therefore be a powerful strategy to inhibit
the activated phenotype of CAFs and consequently
reduce their ability to promote and support tumor cells.
This is supported by a limited number of studies showing
that PDGFR inhibition by Imatinib not only reduces
fibroblast proliferation in vitro [8] but also slows progres-
sion of cervical carcinomas [9], growth of pancreatic car-
cinomas [10], progression and metastasis of colon
carcinomas [7], and improves the uptake of radioimmu-
notherapy in colorectal carcinomas [11]in vivo. More
recently, Nilotinib and Dasatinib, two additional inhibi-
tors of Abl and PDGFR kinases have also been approved
for treatment of CML [12,13]. In analogy to Imatinib,
both inhibitors have been shown to affect fibroblast
growth [14].
As a next step, we studied the effects of four FDA
approved inhibitors Dasatinib, Imatinib, Nilotinib, and
Sorafenib, which all target PDGFR in vitro, in a panel of
CAF strains from individual lung cancer patients. All four
inhibitors blocked CAF growth whereas the EGFR inhibi-
tor Erlotinib, which was used in control experiments, was
inactive at clinically relevant concentrations (Figure 1B).
However, despite the fact that Dasatinib, Imatinib, Nilo-
tinib, and Sorafenib inhibit PDGFR with comparable
IC50 values ranging from 28 nM - 80 nM [15-17], their
effects on proliferation and/or viability of CAF strains
from lung carcinomas in vitro were remarkably different.
Dasatinib was highly efficient in reducing CAF growth
already at concentrations below 100 nM (Figure 1B, left
panel) whereas approximately 10fold higher inhibitor
concentrations were required to achieve a comparable
growth reduction by Imatinib, Nilotinib, and Sorafenib
(Figure 1B, left panel). The most likely explanation for the
diverging biological activities of these PDGFR-inhibitors
is the different spectrum of kinases targeted in addition
t o  P D G F R .  I n  c o n t r a s t  t o  I m a t i n i b ,  N i l o t i n i b ,  a n d
Sorafenib, Dasatinib targets a variety of other kinases
such as Src kinases, TEC kinases, MAP kinases and oth-
ers [18]. Combined inhibition of PDGFR together with
blocking of intracellular signalling cascades may be more
effective than inhibition of PDGFR alone.
Highly different plasma concentrations are achieved in
pharmacokinetic studies with Imatinib, Dasatinib, Nilo-
tinib, and Sorafenib [19-22]. To estimate whether the dif-
fering in vitro activity of these compounds can also be
expected after in vivo exposure we compared inhibitor
concentrations corresponding to Cmax values observed
in clinical studies. All CAFs responded to Dasatinib at a
concentration of 0.11 μM with a reduction of cell growth
by 36.4 ± 1.2% (mean ± SEM). Imatinib was slightly less
effective (31.5 ± 1.8% at 5.3 μM), whereas the inhibitory
effects of Nilotinib and Sorafenib were significantly less
pronounced with a reduction of cell growth by 20.5 ±
2.4% and 16.3 ± 1.2%, respectively (Figure 1B). We then
studied the mechanism of action of the most effective
compounds Dasatinib and Imatinib. Both molecules pri-
marily reduced the fraction of S phase cells as indicated
by a significant reduction of DNA synthesis. The effect of
Dasatinib on inhibition of proliferation was more pro-
nounced than that of Imatinib (74.5 ± 5.9% versus 35.8 ±
7.5%; Figure 1C). No induction of cell death was seen
under these conditions (Figure 1C). Moreover, Dasatinib
did not induce senescence in CAFs as β-galactosidase
staining was not evident in Dasatinib treated CAFs (Fig-
ure 1D). This is further supported by the finding that the
Dasatinib-induced proliferation stop is reversible since
cells were able to re-enter the cell cycle, synthesize DNA,
and proliferate after removal of Dasatinib (Figure 1E).
Therefore, Dasatinib represents a highly active com-
pound to block proliferation in CAFs.
As Dasatinib appeared to be the most effective com-
pound we characterized its molecular effects by perform-
ing microarray analysis (Additional file 1, Material and
Methods) of nine individual CAF strains cultivated in
presence or absence of Dasatinib. We identified 511 tran-
scripts (492 genes) whose expression was changed signifi-
cantly at least twofold (Figure 2A; Additional file 3, Table
S2). Gene ontology analysis identified 107 of these (104
genes) as cell cycle related of whom 97 were downregu-Haubeiss et al. Molecular Cancer 2010, 9:168
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Figure 1 PDGFR inhibitors block proliferation of CAFs without inducing cell death. A, CAFs from two lung adenocarcinomas were cultivated as 
described [27] and incubated with 160 different kinase inhibitors (1 μM each). After 48 hours the efficacy of the inhibitors was monitored by MTT. 
Points represent mean values from two experiments (relative to DMSO-treated controls). Red points represent growth reduction >50% in both strains. 
B, Left panel: MTT experiments performed with indicated inhibitor concentrations. Data represent mean ± SEM from 37 (Dasatinib, Imatinib), 21 (Ni-
lotinib), 7 (Sorafenib), and 10 CAF strains (Erlotinib). Experiments were performed in triplicates. Right panel: MTT experiments with one concentration 
representing Cmax. Statistics was performed using unpaired students t-test (*: p < 0.05). C, Proliferation analyzed by BrdU labelling and PI staining. Left 
panel: representative experiment. Middle panel: percentages of cells in G0/G1, S, and G2/M from CAFs incubated with/without Imatinib (3 μM) or Da-
satinib (0.1 μM) for 24 hours (mean ± SEM from 11 strains. Statistics was performed with paired student's t-test; ***: p < 0.001). Right panel: Annexin V 
staining of CAFs following Imatinib or Dasatinib for 24 hours (mean ± SEM from 11 strains). D, CAFs were stained for β-galactosidase 7 days after treat-
ment with 0.1 μM Dasatinib for 48 hours. As a control we used NAFs cultivated for 5 passages (representative examples). E, Proliferation of CAFs fol-
lowing Dasatinib washout. Cells were treated with Dasatinib for 24 hours. Dasatinib was then washed out and cells were cultivated in drug-free 
medium for indicated times. Samples were analyzed by BrdU labelling and PI staining (representative experiment).
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lated (e.g. CDK2, FOXM1, CDC20, E2F7, MKI67). Of the
remaining 404 transcripts (388 genes), 229 transcripts
(216 genes) were downregulated in the presence of Dasat-
inib. Among these we found additional genes coding for
proteins important for the control of DNA integrity such
as DNA repair proteins (e.g. FANC  genes,  BRCA1/2,
RAD51, XRCC2). 175 transcripts (172 genes) were upreg-
ulated such as genes encoding for receptors (PDGFRB,
ROR1,  CRYAB), ECM and adhesion proteins (such as
MCAM, Integrins, Laminins, Collagens).
Several transcriptome signatures related to the function
of NAFs and CAFs have been reported. As expected, a
significant overlap between the Dasatinib response genes
and genes associated with quiescence in normal fibro-
blasts exists [23] (Additional file 4, Table S3). More
importantly, a quiescence-associated expression pattern
could recently be identified to be of prognostic value in
epithelial tumors [24,25]. These authors defined core
serum response genes not related to cell cycle processes
in fibroblasts as genes differentially regulated upon addi-
tion of serum to the culture medium. Dasatinib downreg-
ulated 26 of the 214 serum induced genes. Accordingly,
Dasatinib upregulated 17 of the 202 genes whose expres-
sion was blocked by addition of serum (p < 10-12; Fisher's
exact test). Thus, a significant number of genes were reg-
ulated by Dasatinib treatment in the same direction as by
growth factor withdrawal (Figure 3A; Additional file 5,
Table S4). This is in line with the observation that Dasat-
inib induces a quiescent state in CAFs.
However, many genes of the Dasatinib response signa-
ture are not overlapping with the serum-repressed pat-
tern. This observation supports the view that Dasatinib
induces more than a quiescence-like phenotype in fibro-
blasts. We therefore compared the Dasatinib response
signature to the published differential expression pattern
of NAFs and CAFs from breast cancer cases [26]. 64 of
the genes found to be downregulated by Dasatinib were
also lower expressed in NAFs compared to CAFs, while
only 8 genes should be expected by chance alone (p < 10-
30; Fisher's exact test). Furthermore, 26 genes were upreg-
ulated in CAFs treated with Dasatinib and also in NAFs
(4 genes by chance alone; p < 10-11) (Figure 3B; Additional
file 6, Table S5). We selected 6 genes from the 90 genes in
the overlap for validation by qRT-PCR (Additional file 1,
Material and Methods). Two of them were overexpressed
(PDGFR and SVEP1). The expression of both could be
confirmed to be significantly higher in Dasatinib treated
CAFs by qRT-PCR. Four genes downregulated by Dasat-
inib and lower expressed in NAFs (MMP1, MKI67, TTK,
and FOXM1) were confirmed to be reduced by qRT-PCR,
reaching significance for MMP1,  TTK  and  FOXM1
(Additional file 7, Figure S1).
To assess whether the observed Dasatinib-mediated
alteration of CAFs may influence tumor cell growth, we
Figure 2 Effect of Dasatinib on gene expression. Heatmap of tran-
scripts regulated by Dasatinib. Cell cycle related transcripts are shown 
in the left panel and transcripts not related to cell cycle in the right 
panel. Nine CAF strains isolated from 9 different lung carcinoma spec-
imens were incubated with or without Dasatinib for 48 hours and an-
alyzed with microarrays. Transcripts regulated by Dasatinib were 
identified by a significant 2fold change. The relative expression levels 
for a gene among the samples are indicated by green for low value and 
by red for high value. Each row represents a transcript; each column 
represents one sample (see also: Additional file 3, Table S2).
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Figure 3 Relationship of Dasatinib regulated genes with functional datasets resembling quiescence [24]and normal fibroblasts [26]. A, Venn 
diagrams depicting the number of genes differentially regulated by Dasatinib only, by Dasatinib and serum, and by serum only (upper panel). Both 
the overlap of genes downregulated and upregulated in both datasets is highly significant (p = 1.5 × 10-17 and p = 2.0 × 10-12; Fisher's exact test). The 
lower panel represents the heatmap of the overlap between Dasatinib regulated genes and core serum response genes. B, Venn diagrams depicting 
the number of genes regulated by Dasatinib only, differentially expressed in CAFs in absence or presence of Dasatinib and in CAFs vs. NAFs, and genes 
differentially expressed in CAFs vs. NAFs only (upper panel). The overlap of genes downregulated and upregulated in both datasets is highly significant 
(p = 6.6 × 10-30 and p = 2.3 × 10-11; Fisher's exact test). Heatmap of expression patterns of Dasatinib regulated genes overlapping with genes differen-
tially regulated in CAFs vs. NAFs (lower panel).
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tested the effect of Dasatinib alone and that of condi-
tioned medium (CM) from CAFs pre-incubated with or
without Dasatinib on cell cycle and DNA synthesis of
H1299 lung cancer cells. At low serum concentration
CAF conditioned medium significantly enhanced tumor
cell proliferation. This tumor promoting activity was
completely abolished in CM from CAFs pre-treated with
Dasatinib. Importantly, the reduction of tumor cell prolif-
Figure 4 Conditioned medium from Dasatinib-treated CAFs inhibits tumor cell proliferation. H1299 epithelial tumor cells were cultivated with 
conditioned medium (CM; plots 3, 4, and 5) or control medium (plots 1 and 2) for 48 hours before harvesting for BrdU labelling and propidium iodide 
staining. CM was collected from CAFs cultivated in the presence or absence of Dasatinib for 48 h in medium supplemented with 0.1% FCS. Control 
medium (0.1% FCS) with or without Dasatinib was collected following incubation for 48 h without cells. Upper panel: representative result; lower pan-
el: absolute reduction of the percentage of BrdU positive tumor cells in S phase upon Dasatinib. Dasatinib was either added to control medium in the 
absence of cells (first bar; 2 minus 1), to CAF conditioned medium after collecting CM (second bar; 4 minus 3), or to CAFs for 48 hours before collecting 
CM (third bar; 5 minus 3). Values reflect means ± SEM from 3 independent experiments (statistics was performed with paired student's t-test, 2-tailed, 
Holm corrected; ***: p < 0.001).
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eration by CM from CAFs pre-treated with Dasatinib was
significantly more pronounced than that observed with
Dasatinib alone (Figure 4).
In conclusion, our data demonstrate that Dasatinib
treatment partially reverses the CAF phenotype in fibro-
blasts from lung cancer tissues. More importantly, treat-
ment of CAFs with Dasatinib reduces their ability to
promote tumor proliferation in vitro. Treatment of lung
cancer with Dasatinib may therefore be a promising strat-
egy to enhance the efficacy of conventional therapy.
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